Full-Time
Clinical evidence generation for trials
No salary listed
Senior
Remote in USA
Upload your resume to see how it matches 12 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Clario specializes in generating clinical evidence for medical research by combining scientific expertise with a wide range of endpoint technology. Their products support various types of clinical trials, including decentralized, hybrid, and site-based trials, allowing for flexibility in how studies are conducted. Clario stands out from competitors due to its extensive experience, having participated in nearly 19,000 clinical trials and achieved 870 regulatory approvals, which provides a high level of reliability in the data they produce. The company's goal is to empower partners in the healthcare industry to improve patient outcomes by providing comprehensive and trustworthy clinical evidence.
Company Size
5,001-10,000
Company Stage
Growth Equity (Venture Capital)
Total Funding
$29.9M
Headquarters
London, United Kingdom
Founded
1972
Help us improve and share your feedback! Did you find this helpful?
Competitive and equitable total rewards package
Physical, mental and financial health and wellness
Flexible working approach
NeuroRx founder and CEO Douglas Arnold, M.D., is also joining Clario as a senior scientific advisor, Clario announced in a March 17 release.
Clario, a Philadelphia-based provider of endpoint data solutions to the clinical trial industry, has acquired NeuroRx, a Montreal-based provider of imaging analysis on multiple sclerosis.
Clario, a leader in endpoint data solutions for clinical trials, has acquired NeuroRx, an imaging analysis expert in multiple sclerosis. This acquisition enhances Clario's neuroscience capabilities. NeuroRx's founder, Douglas Arnold, M.D., will join Clario as Senior Scientific Advisor. Clario also plans to acquire WCG’s eCOA business, further strengthening its neuroscience expertise.
Acquisition of WCG's electronic clinical outcome assessments (eCOA) business will expand Clario's scientific expertise and offerings in neurosciencePHILADELPHIA, March 10, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have entered into a definitive agreement to acquire the eCOA business of WCG, a leader in providing solutions that measurably improve and accelerate clinical research. Electronic clinical outcomes assessments (eCOA), in addition to paper assessments, are used to evaluate the safety and efficacy of new drugs by measuring how a clinical trial participant feels or functions. WCG's eCOA operations offer robust, full-service clinical expertise and specialized functionality, particularly in neurology, psychiatry, neuropathic pain, and rare diseases
PHILADELPHIA - October 10, 2024 - Clario, a leading provider of endpoint data solutions to the clinical trials industry, is excited to announce a strategic partnership with PathAI, a leader in AI-powered digital pathology solutions aimed at improving diagnostic accuracy and efficiency.